AU2001294793B2 - Viruses targeted to hypoxic cells and tissues - Google Patents

Viruses targeted to hypoxic cells and tissues Download PDF

Info

Publication number
AU2001294793B2
AU2001294793B2 AU2001294793A AU2001294793A AU2001294793B2 AU 2001294793 B2 AU2001294793 B2 AU 2001294793B2 AU 2001294793 A AU2001294793 A AU 2001294793A AU 2001294793 A AU2001294793 A AU 2001294793A AU 2001294793 B2 AU2001294793 B2 AU 2001294793B2
Authority
AU
Australia
Prior art keywords
cells
hypoxia
virus
gene
recombinant virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2001294793A
Other languages
English (en)
Other versions
AU2001294793A1 (en
Inventor
Ainsley C. Nicholson
Dawn E. Post
Erwin Van Meir
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Emory University
Original Assignee
Emory University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emory University filed Critical Emory University
Publication of AU2001294793A1 publication Critical patent/AU2001294793A1/en
Application granted granted Critical
Publication of AU2001294793B2 publication Critical patent/AU2001294793B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/20—Vector systems having a special element relevant for transcription transcription of more than one cistron
    • C12N2830/205—Vector systems having a special element relevant for transcription transcription of more than one cistron bidirectional
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2001294793A 2000-09-26 2001-09-26 Viruses targeted to hypoxic cells and tissues Ceased AU2001294793B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23528300P 2000-09-26 2000-09-26
US60/235,283 2000-09-26
PCT/US2001/030236 WO2002026192A2 (en) 2000-09-26 2001-09-26 Viruses targeted to hypoxic cells and tissues

Publications (2)

Publication Number Publication Date
AU2001294793A1 AU2001294793A1 (en) 2002-06-20
AU2001294793B2 true AU2001294793B2 (en) 2006-06-29

Family

ID=22884861

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2001294793A Ceased AU2001294793B2 (en) 2000-09-26 2001-09-26 Viruses targeted to hypoxic cells and tissues
AU9479301A Pending AU9479301A (en) 2000-09-26 2001-09-26 Viruses targeted to hypoxic cells and tissues

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU9479301A Pending AU9479301A (en) 2000-09-26 2001-09-26 Viruses targeted to hypoxic cells and tissues

Country Status (7)

Country Link
EP (1) EP1328291B1 (https=)
JP (1) JP4709471B2 (https=)
AT (1) ATE418342T1 (https=)
AU (2) AU2001294793B2 (https=)
CA (1) CA2423833C (https=)
DE (1) DE60137137D1 (https=)
WO (1) WO2002026192A2 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1545627A4 (en) * 2002-10-01 2006-12-27 Univ Duke TARGETED TUMOR THERAPY THROUGH THE USE OF RECOMBINANT ADENOVIRUS VECTORS FOR SELECTIVE REPLICATION IN HYPOXIC TUMOR REGIONS
US20040142558A1 (en) 2002-12-05 2004-07-22 Granneman Ernst H. A. Apparatus and method for atomic layer deposition on substrates
US7537662B2 (en) 2003-04-29 2009-05-26 Asm International N.V. Method and apparatus for depositing thin films on a surface
US7601223B2 (en) 2003-04-29 2009-10-13 Asm International N.V. Showerhead assembly and ALD methods
EP1736546A4 (en) * 2004-03-23 2008-03-05 Eisai R&D Man Co Ltd METHOD FOR MEASURING TRANSCRIPTION ACTIVITY, METHOD FOR MEASURING CELL QUANTITY, AND TUMOR VOLUME MEASURING METHOD USING NON-HUMAN ANIMAL MODEL
US8487087B2 (en) 2005-03-11 2013-07-16 Oriental Yeast Co., Ltd. Model animal in which state of disease condition is observable in real time, gene construct for achieving the same and use of the same
CN108623693B (zh) * 2017-03-20 2022-03-25 徐寒梅 一种融合蛋白及其制备方法和其在制备治疗眼科疾病、抗炎、抗肿瘤药物中的应用
CN116064675B (zh) * 2022-07-22 2024-12-03 西安电子科技大学 一种重组质粒、重组慢病毒载体、稳转细胞系及其构建方法与应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5783435A (en) * 1996-08-06 1998-07-21 Lamparski; Henry G. Prostate cancer drug screenings
BR9813917A (pt) * 1997-11-03 2001-10-30 Univ Arizona Vetores de expressão induzìveis hipertérmicospara terapia de genetica e métodos de uso dos mesmos
US6900049B2 (en) * 1998-09-10 2005-05-31 Cell Genesys, Inc. Adenovirus vectors containing cell status-specific response elements and methods of use thereof

Also Published As

Publication number Publication date
JP4709471B2 (ja) 2011-06-22
EP1328291B1 (en) 2008-12-24
EP1328291A4 (en) 2005-07-06
CA2423833C (en) 2011-02-22
WO2002026192A2 (en) 2002-04-04
EP1328291A2 (en) 2003-07-23
ATE418342T1 (de) 2009-01-15
JP2004509635A (ja) 2004-04-02
DE60137137D1 (de) 2009-02-05
AU9479301A (en) 2002-04-08
CA2423833A1 (en) 2002-04-04
WO2002026192A3 (en) 2002-08-08

Similar Documents

Publication Publication Date Title
US7048920B2 (en) Recombinant oncolytic adenovirus for human melanoma
EP1767642B1 (en) Construction of oncolytic adenovirus recombinant specifically expressing immune modulatory factor gm-csf in tumor cells and uses thereof
CA2206179C (en) Vectors for tissue-specific replication
Hernandez-Alcoceba et al. A novel, conditionally replicative adenovirus for the treatment of breast cancer that allows controlled replication of E1a-deleted adenoviral vectors
Lambright et al. Inclusion of the herpes simplex thymidine kinase gene in a replicating adenovirus does not augment antitumor efficacy
EP1002103A1 (en) A human glandular kallikrein enhancer, vectors comprising the enhancer and methods of use thereof
WO1996017053A9 (en) Vectors for tissue-specific replication
JP2013543386A (ja) 組み換えられた遺伝子発現調節配列を有する腫瘍特異的発現の改善された遺伝子伝達システム
AU699867B2 (en) Recombinant adenoviruses for gene therapy in cancers
KR20210089135A (ko) 글리코겐 합성효소 키나아제-3(gsk3)에 대한 코딩 영역을 포함하는 재조합 복제 가능 바이러스 및 비정상 세포 사멸 방법
AU2001294793B2 (en) Viruses targeted to hypoxic cells and tissues
US7285414B2 (en) Viruses targeted to hypoxic cells and tissues
EP1071805B1 (en) Adenoviral vectors for treating disease
AU2001294793A1 (en) Viruses targeted to hypoxic cells and tissues
JP2004509635A5 (https=)
WO1999044423A1 (en) Amplification of gene transfer and gene therapy by controlled replication
Lesniak Gene therapy for malignant glioma
US20040101825A1 (en) Viruses targeted to hypoxic cells and tissues
US20060275262A1 (en) Conditionally replicating viruses and methods for cancer virotherapy
Voronova et al. Obtaining a new gene-cell construct based on transduced olfactory Ensheathing cells for the treatment of spinal cord injuries
WO1996036365A1 (en) Gene therapy of hepatocellular carcinoma through cancer-specific gene expression
CN115651932A (zh) 一种靶向消化道肿瘤双靶向溶瘤腺病毒的构建方法及其应用
Zhang et al. Gene therapy for oral squamous cell carcinoma with IAI. 3B promoter-driven oncolytic adenovirus-infected carrier cells
Jung et al. Cytotoxic effect of a replication-incompetent adenoviral vector with cytosine deaminase gene driven by L-plastin promoter in hepatocellular carcinoma cells
AU2005337612A1 (en) Conditionally replicating viruses and methods for cancer virotherapy

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired